AFFILIATIONS
1 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
2 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
3 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
4 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
5 Department of Hematology/Hematopoietic Stem Cell Transplantation Center, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China, Tianjin, China
6 Department of Hematology/Hematopoietic Stem Cell Transplantation Center, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China, Tianjin, China
7 Department of Hematology, Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, Wuhan, China
8 Department of Hematology, Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, Wuhan, China
9 Department of Hematology, Guangdong Provincial Hospital of Chinese Medicine, The Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, China, Guangzhou, China
10 Department of Hematology, Guangzhou First People's Hospital, South China University of Technology/Guangzhou Medical University, Guangzhou, China, Guangzhou, China
11 Department of Hematology, First Affiliated Hospital of Nanchang University, Nanchang, China, Nanchang, China
12 Department of Hematology, Peking University Shenzhen Hospital, Shenzhen, China, Shenzhen, China
13 Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China., Wuhan, China
14 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
15 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
16 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
17 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
18 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
19 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
20 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
21 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
22 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
23 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
24 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
25 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
26 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
27 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
28 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
29 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
30 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
31 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
32 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
33 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
34 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
35 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
36 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
37 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
38 Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, Wuhan, China
39 Department of Hematology, Peking University Shenzhen Hospital, Shenzhen, China, Shenzhen, China
40 Department of Hematology, First Affiliated Hospital of Nanchang University, Nanchang, China, Nanchang, China
41 Department of Hematology, Guangzhou First People's Hospital, South China University of Technology/Guangzhou Medical University, Guangzhou, China, Guangzhou, China
42 Department of Hematology, Guangdong Provincial Hospital of Chinese Medicine, The Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, China, Guangzhou, China
43 Department of Hematology, First Affiliated Hospital, Harbin Medical University, Harbin, China, Harbin, China
44 Department of Hematology, Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, Wuhan, China
45 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
46 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
47 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
48 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
49 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China